Yvonne Ceder

Dr. Yvonne Ceder

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ZHZandra Hagman
Zandra Hagman
OLOlivia Larne
Olivia Larne
AEAnders Edsjö
Anders Edsjö
ABAnders Bjartell
Anders Bjartell
RERoy A. Ehrnström
Roy A. Ehrnström
YCYvonne Ceder
Yvonne Ceder
MicroRNAs (miRNAs) are small noncoding RNAs that post‐transcriptionally regulate gene expression. There have been several reports of miRNA deregulation in prostate cancer (PCa) and the biological evidence for an involvement of miRNAs in prostate tumorigenesis is increasing. In this study, we show that miR‐34c is downregulated in PCa (p = 0.0005) by performing qRT‐PCR on 49 TURPs from PCa patients compared to 25 from patients with benign prostatic hyperplasia. The miR‐34c expression was found to inversely correlate to aggressiveness of the tumor, WHO grade, PSA levels and occurrence of metastases. Furthermore, a Kaplan–Meier analysis of patient survival based on miR‐34c expression levels divided into low (< 50th percentile) and high (> 50th percentile) expression, significantly divides the patients into high risk and low risk patients (p = 0.0003, log‐rank test). The phenotypic effects of miR‐34c deregulation were studied in prostate cell lines, where ectopic expression of miR‐34c decreased cell growth, due to both a decrease in cellular proliferation rate and an increase in apoptosis. In concordance to this, miR‐34c was found to negatively regulate the oncogenes E2F3 and BCL‐2, which stimulates proliferation and suppress apoptosis in PCa cells, respectively. Reversely, we could also show that blocking miR‐34c in vitro increases cell growth. Further, ectopic expression of miR‐34c was found to suppress migration and invasion. Our findings provide new insight into the role of miR‐34c in the prostate, exhibiting tumor suppressing effects on proliferation, apoptosis and invasiveness.

28 May 2018 in Analytical Chemistry
Verified
Journal Article
Closed access
AKAnson Ku
Anson Ku
HLHooi Ching Lim
Hooi Ching Lim
MEMikael Evander
Mikael Evander
HLHans Lilja
Hans Lilja
TLThomas Laurell
Thomas Laurell
YCYvonne Ceder
Yvonne Ceder

9 April 2013 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ZHZ Hagman
Z Hagman
BHB S Haflidadóttir
B S Haflidadóttir
JCJ A Ceder
J A Ceder
OLO Larne
O Larne
ABA Bjartell
A Bjartell
YCYvonne Ceder
Yvonne Ceder
The microRNA-205 (miR-205) has been shown to be deregulated in prostate cancer (PCa). Here we continue to investigate the prognostic and therapeutic potential of this microRNA. The expression of miR-205 is measured by qRT–PCR and in situ hybridisation in a well-documented PCa cohort. An AGO2-based RIP-Chip assay is used to identify targets that are verified with western blots, luciferase reporter assay, ELISA and immunohistochemistry. The expression of miR-205 is inversely correlated to the occurrence of metastases and shortened overall survival, and is lower in castration-resistant PCa patients. The miR-205 expression is mainly localised to the basal cells of benign prostate tissues. Genes regulated by miR-205 are enriched in, for example, the MAPK/ERK, Toll-like receptor and IL-6 signaling pathways. We demonstrate binding of miR-205 to the 3′UTR of androgen receptor (AR) and decrease of both AR transcript and protein levels. This finding was corroborated in the patient cohort were miR-205 expression inversely correlated to AR immunostaining in malignant prostate cells and to serum levels of prostate-specific antigen, an androgen-regulated protein. Taken together, these findings imply that miR-205 might have therapeutic potential, especially for the castration resistant and currently untreatable form of PCa.

26 July 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CAChandrani Achari
Chandrani Achari
SWSofia Winslow
Sofia Winslow
YCYvonne Ceder
Yvonne Ceder
CLChrister Larsson
Christer Larsson
MicroRNA-34 is a family of three miRNAs that have been reported to function as tumor suppressor miRNAs and show decreased expression in various cancers. Here, we examine functions of miR-34c in basal-like breast cancer cells. Data from The Cancer Genome Atlas (TCGA) were used for evaluation of expression in primary breast cancers. Cellular processes affected by miR-34c were investigated by thymidine incorporation, Annexin V-assays and cell cycle analysis using breast cancer cell lines. Effects on potential targets were analyzed with qPCR and Western blot. TCGA data revealed that miR-34c was expressed at lower levels in basal-like breast cancer tumors and low expression was associated with poor prognosis. Ectopic expression of miR-34c in basal-like breast cancer cell lines resulted in suppressed proliferation and increased cell death. Additionally, miR-34c influenced the cell cycle mainly by inducing an arrest in the G2/M phase. We found that expression levels of the known cell cycle-regulating miR-34 targets CCND1, CDK4 and CDK6, were downregulated upon miR-34c expression in breast cancer cell lines. In addition, the levels of CDC23, an important mediator in mitotic progression, were suppressed following miR-34c expression, and siRNAs targeting CDC23 mimicked the effect of miR-34c on G2/M arrest. However, protein levels of PRKCA, a predicted miR-34c target and a known regulator of breast cancer cell proliferation were not influenced by miR-34c. Together, our results support the role of miR-34c as a tumor suppressor miRNA also in breast cancer.

27 November 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
OLOlivia Larne
Olivia Larne
EMElena S. Martens-Uzunova
Elena S. Martens-Uzunova
ZHZandra Hagman
Zandra Hagman
AEAnders Edsjö
Anders Edsjö
GLGiuseppe Lippolis
Giuseppe Lippolis
YCYvonne Ceder
Yvonne Ceder
Today, the majority of prostate tumors are detected at early stages with uncertain prognosis. Therefore, we set out to identify early predictive markers of prostate cancer with aggressive progression characteristics. We measured the expression of microRNAs (miRNA) using qRT‐PCR in formalin fixed and paraffin embedded prostatic tissue samples from a Swedish cohort of 49 patients with prostate cancer and 25 without cancer and found seven of 13 preselected miRNAs to discriminate between the two groups. Subsequently, four discriminatory miRNAs were combined to a quota, denoted the miRNA index quote (miQ); ((miR‐96‐5p × miR‐183‐5p)/(miR‐145‐5p × miR221‐5p)). The advantage of using a quote is increased discrimination, no need for house‐keepings, and most important it may be an advantage considering the heterogeneity of the disease. miQ was found to successfully predict diagnosis (p < 0.0001) with high accuracy (area under the curve, AUC = 0.931) that was verified in an independent Dutch cohort and three external cohorts, and significantly outperforming prostate‐specific antigen. Importantly, miQ also has prognostic power to predict aggressiveness of tumors (AUC = 0.895), metastatic statues (AUC = 0.827) and overall survival (p = 0.0013, Wilcoxon test HR = 6.5, median survival 2 vs. 5 years), verified in the Dutch cohort. In this preliminary study, we propose that miQ has potential to be used as a clinical tool for prostate cancer diagnosis and as a prognostic marker of disease progression.

12 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BHBenedikta S. Haflidadóttir
Benedikta S. Haflidadóttir
OLOlivia Larne
Olivia Larne
MMMyriam Martin
Myriam Martin
MPMargareta Persson
Margareta Persson
AEAnders Edsjö
Anders Edsjö
YCYvonne Ceder
Yvonne Ceder
Aberrant expression of miR-96 in prostate cancer has previously been reported. However, the role and mechanism of action of miR-96 in prostate cancer has not been determined. In this study, the diagnostic and prognostic properties of miR-96 expression levels were investigated by qRT-PCR in two well documented prostate cancer cohorts. The miR-96 expression was found to be significantly higher in prostate cancer patients and correlate with WHO grade, and decreased overall survival time; patients with low levels of miR-96 lived 1.5 years longer than patients with high miR-96 levels. The therapeutic potential was further investigated in vitro, showing that ectopic levels of miR-96 enhances growth and cellular proliferation in prostate cancer cells, implying that miR-96 has oncogenic properties in this setting. We demonstrate that miR-96 expression decreases the transcript and protein levels of FOXO1 by binding to one of two predicted binding sites in the FOXO1 3'UTR sequence. Blocking this binding site completely inhibited the growth enhancement conveyed by miR-96. This finding was corroborated in a large external prostate cancer patient cohort where miR-96 expression inversely correlated to FOXO1 expression. Taken together these findings indicate that miR-96 plays a key role in prostate cancer cellular proliferation and can enhance prostate cancer progression. This knowledge might be utilized for the development of novel therapeutic tools for prostate cancer.